DOI: 10.1007/s00259-018-4146-5Pages: 2442-2455

Translational molecular imaging in exocrine pancreatic cancer

1. Oxford University, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology

2. Istituto Oncologico Veneto I.R.C.C.S.

3. Vrije Universiteit Brussel

4. Universitätsspital Basel, Department of Radiology

5. Universita’ degli Studi di Napoli “Federico II”

6. CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes

7. Erasmus MC, Department of Radiology & Nuclear Medicine

8. Leiden University Medical Center, Interventional Molecular Imaging Laboratory, Department of Radiology

Correspondence to:
Bart Cornelissen
Email: bart.cornelissen@oncology.ox.ac.uk

Close

Abstract

Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management.

This article is freely available, click here to access the full text/PDF

  • Accepted: Aug 22, 2018
  • Online: Sep 17, 2018

Article Tools

eanm
EJNMMI Ad